Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an essential regulator of T-cell responses, and its absence precipitates lethal T-cell hyperactivity. However, whether CTLA-4 acts simply to veto the activation of certain clones or plays a more nuanced role in shaping the quality of T-cell responses is not clear. Here we report that T cells in CTLA-4-deficient mice show spontaneous Tfollicular helper (T FH ) differentiation in vivo, and this is accompanied by the appearance of large germinal centers (GCs). Remarkably, short-term blockade with anti-CTLA-4 antibody in wild-type mice is sufficient to elicit T FH generation and GC development. The latter occurs in a CD28-dependent manner, consistent with the known role of CTLA-4 in regulating the CD28 pathway. CTLA-4 can act by down-regulating CD80 and CD86 on antigen presenting cells (APCs), thereby altering the level of CD28 engagement. To mimic reduced CD28 ligation, we used mice heterozygous for CD28, revealing that the magnitude of CD28 engagement is tightly linked to the propensity for T FH differentiation. In contrast, other parameters of T-cell activation, including CD62L down-regulation and Ki67 expression, were relatively insensitive to altered CD28 level. Altered T FH generation as a result of graded reduction in CD28 was associated with decreased numbers of GC B cells and a reduction in overall GC size. These data support a model in which CTLA-4 control of immunity goes beyond vetoing T-cell priming and encompasses the regulation of T FH differentiation by graded control of CD28 engagement.
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T cell | costimulation | CD28 | CTLA-4 | autoimmunity C ontrol of the magnitude and nature of adaptive immune responses is critical for health. The cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4)/CD28 axis has long been known to control the magnitude of T-cell responses, however whether it also influences their nature has not been clear. Early studies suggested that CD28 may be particularly important for Th2 differentiation (1, 2) , although others identified roles for CD28 in both Th1 and Th2 responses (3, 4) . It is known that CD28 is an absolute requirement for the differentiation of follicular helper T cells (T FH s) that support germinal center (GC) formation (5, 6) . However, these studies generally make use of CD28-deficient T cells, and therefore, results may reflect a failure of the cells to properly activate, proliferate, or survive, particularly given the known contribution of CD28 to these processes.
A key outstanding question is whether CD28 costimulation in vivo is more complex than a binary checkpoint for T-cell priming. It is clear that expression of costimulatory ligands on antigen presenting cells (APCs) fluctuates in response to environmental stimuli, being up-regulated by inflammatory cytokines and TLR agonists and down-regulated by Treg-expressed CTLA-4 (7-11). Thus, variable levels of costimulatory ligands will be available for CD28 binding depending on the microenvironmental context. However, whether this simply alters the number of T cells that achieve the required threshold to commit to a response or whether it influences the nature of the response is not clear. Effective immune homeostasis appears to be reliant on maintaining an appropriate level of CD28 engagement. For example, basal expression of CD28 ligands, in particular dendritic cell-expressed CD86 (12) , is critical to Treg homeostasis (13, 14) , whereas excessive CD28 engagement in the absence of CTLA-4 results in lethal autoimmunity (15, 16) . Nonetheless, distinguishing whether these effects are simply quantitative is not straightforward. Thus, although levels of CD28 ligands are clearly variable in vivo, our understanding of the impact of altering the level of CD28 engagement is still incomplete.
To explore the impact of varying levels of CD28 ligation, we have used the CTLA-4-deficient mouse as a model of excessive CD28 stimulation. In these mice, we observed a striking skewing toward T FH differentiation, with induction of IL-21 and spontaneous formation of GCs. In a complementary approach, we used CD28 heterozygosity to decrease T cell CD28 expression: This revealed that the level of CD28 engagement is tightly coupled to the level of inducible T-cell costimulator (ICOS) induction, T FH generation, and GC formation, whereas other parameters of T-cell activation were less affected. Finally, we demonstrate that induction of the microRNA cluster miR17-92, recently linked with T FH differentiation (17, 18) , varies proportionally with APC costimulatory ligand expression and is modulated by CTLA-4 deficiency or blockade. Collectively, these data suggest that the CTLA-4/CD28 axis provides quantitative and qualitative control of T-cell help for humoral immunity.
Results CTLA-4 Deficiency or Blockade Augments T FH Numbers. Mice lacking CTLA-4 exhibit a lethal CD28-dependent lymphoproliferative syndrome with evidence of skewing to Th2 (19) . However, the impact of CTLA-4 deficiency on T FH differentiation has not previously been examined. We therefore analyzed spleen (Fig. 1) 
Significance
The inhibitory protein cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is recognized as a crucial regulator of autoimmunity, but its precise mechanism of action is not yet fully understood. CTLA-4 can down-regulate expression of the costimulatory ligands CD80 and CD86 on antigen presenting cells, thereby reducing T-cell CD28 engagement. Here we demonstrate that quantitative changes in the level of CD28 engagement have functional consequences for T-cell differentiation toward follicular helper T cells (T FH s). These findings link CTLA-4 control of T-cell responses with the generation of highaffinity class-switched antibody responses. This generates an advanced conceptual framework for understanding the linked nature of CTLA-4 and CD28 functions and the role of this pathway in influencing autoimmunity.
and lymph node (Fig. S1 ) CD4 T cells for expression of a panel of T FH markers. CD4 T cells from CTLA-4-deficient mice expressed elevated levels of the T FH markers PD-1 and CXCR5 (Fig. 1A) . IL-21, the archetypal cytokine associated with T FH differentiation, was up-regulated at the mRNA (Fig. S1C) and protein (Fig. 1B) level in conventional T cells (Tconv) from CTLA-4-deficient mice compared with age-matched wild-type controls. Consistent with augmented T FH differentiation, B cells with a GC phenotype (Fas+GL-7+) were readily detectable in the lymph nodes (LNs) and spleens of CTLA-4-deficient mice ( Fig. 1C and Fig. S1 ), and immunohistological analysis revealed spontaneous GC formation (Fig. 1D) . The systemic immune dysregulation associated with CTLA-4 deficiency makes it hard to establish whether features observed in these animals reflect a direct effect of CTLA-4 deficiency or a secondary effect of disease. Indeed, the T-cell compartment in CTLA-4-deficient mice shows evidence of extensive activation (Fig. S2) . We therefore performed short-term CTLA-4 blockade studies in wild-type mice. Remarkably, short-term blockade of CTLA-4 was sufficient to induce the appearance of T FH cells ( Fig. 2A) , GC B cells (Fig. 2B) , and immunohistologically evident GCs (Fig. 2C) in the spleen. Similar effects were noted in the LNs (Fig. S3 A and B) . There was marked Bcl6 up-regulation in CD4 T cells from anti-CTLA-4 Ab-injected mice (Fig. 2D) . GC formation could be detected as early as 3 d following anti-CTLA-4 Ab injection (Fig. S4A) , and injection of control Ab did not induce GC formation (Fig. S4B) . Importantly, GC formation was CD28-dependent, as anti-CTLA-4 Ab did not elicit spontaneous GC formation in CD28-deficient mice (Fig. S4C) . To assess whether GC formation following CTLA-4 blockade was associated with autoantibody production, we first used serum from CTLA-4-deficient mice to confirm a suitable target autoantigen. Serum from CTLA-4-deficient, but not wild-type mice, stained stomach sections from Rag2 −/− mice (Fig. S5A) , consistent with the previous demonstration that deficiency of CTLA-4 in Treg triggers the production of antiparietal cell antibodies (Abs) and autoimmune gastritis (9) . Interestingly, serum from mice treated with anti-CTLA-4 Ab also showed reactivity to Rag2 −/− stomach sections, whereas serum from control-treated mice did not (Fig. S5B ). In addition, anti-dsDNA Abs were detected in mice treated with anti-CTLA-4 Ab (Fig.  S5C) . Collectively, these data indicate that the CTLA-4 pathway controls T FH development in a CD28-dependent manner and that persistent CTLA-4-mediated regulation is required to prevent the spontaneous emergence of T FH s, GCs, and autoantibodies.
Quantitative Effect of CD28 on T FH Development. Because the phenotype of CTLA-4 −/− mice is likely due to excessive CD28 engagement (20, 21) , we hypothesized that the GC response should also be influenced by directly affecting levels of CD28 on T cells. To probe whether changing the amount of CD28 engagement on Tconv altered their ability to support GC formation, we performed adoptive transfer experiments comparing CD28
+/+ , CD28 +/− , and CD28 −/− T cells. In this way, we were able to alter the level of CD28 available for ligation on the T cells, as CD28 expression was markedly lower on CD28 +/− T cells compared with CD28 +/+ T cells (Fig. S6A) . Importantly, heterozygosity, rather than total deficiency, offers a better model of raising or lowering the level of CD28 engagement that could result from Treg-mediated ligand down-regulation on APCs. To ensure the absence of background GCs at the start of the experiment, CD28
−/− mice were used as recipients; thus, in this system, the ability to support GC formation is restricted to the adoptively transferred T cells. DO11 T cells that were CD28
−/− were transferred, and recipient mice were immunized intraperitoneally with alum-precipitated hapten-conjugated ovalbumin (NP-OVA).
DO11 T cells from CD28 +/− mice showed a markedly reduced propensity to acquire a T FH phenotype (based on coexpression of CXCR5 and PD1) (Fig. 3A) compared with their CD28 +/+ counterparts, and this correlated with a decreased number of B cells bearing a GC B-cell phenotype (Fig. 3B) . We noted that average GC size was also decreased in mice receiving CD28 +/− T cells (Fig. 3C ) and that Ab titres were lower than in recipients of CD28 +/+ T cells (Fig. S7A) . A major pathway implicated in the generation of GC responses is the ICOS pathway, the absence of which is associated with a defect in GC formation (22) (23) (24) (25) . T cells from CD28 +/− mice also showed a graded decrease in ICOS expression, with ICOS levels being intermediate compared with CD28 +/+ and CD28 −/− T cells (Fig. 3D) . Interestingly, not all activation markers were similarly affected by CD28 heterozygosity: CD62L down-regulation in CD28 +/− T cells was similar to that seen in wild-type T cells, and Ki67 levels were comparable, indicating equivalent proliferation ( Fig. 3 E and F) . Analysis of Cell Trace profiles at early time points confirmed the similar proliferative response of CD28 +/+ and CD28 +/− T cells (Fig.  S7B ). It should be noted that the percentage and absolute number of DO11 T cells recovered was broadly equivalent for CD28 +/+ and CD28 +/− cells but very low for CD28 −/− cells, consistent with poor T-cell survival in the complete absence of CD28 (Fig. 3G) . Taken together, these data reveal that T-cell activation in the context of reduced CD28 engagement has a marked effect on T FH differentiation, while minimally altering CD62L down-regulation, proliferation, and survival.
CD86 Is the Dominant Ligand for T FH Development. Because the acquisition of a T FH phenotype, and support for GC formation, was clearly modulated by CD28 signaling, we sought to identify the CD28 ligand driving this process. Adoptive transfer experiments were performed using CD28 +/+ DO11 T cells, and blocking Abs were injected against CD80, CD86, or both. The capacity of the CD80 and CD86 Ab to block their respective ligands was verified in vitro (Fig. S8A) . Blockade of CD80 had only a modest effect on the frequency of T FH cells (Fig. 4A) , and this was associated with a marked but incomplete reduction in GC B cells (Fig. 4B) . In contrast, in the presence of CD86 Ab, the percentage of T FH cells was severely reduced-virtually to the same extent as when CD86 and CD80 were both blocked (Fig. 4A) . The frequency of GC B cells was similarly impaired with CD86 blockade, to a comparable extent as with the simultaneous blockade of both ligands (Fig. 4B) . The pattern of ICOS expression showed the same trend (Fig. 4C) , whereas the data suggested a higher degree of redundancy between ligands for IL-21 production (Fig. 4D) . Effects of ligand blockade on production of IFNγ and IL-17 and on CD62L expression are shown in Fig. S8B . Collectively, these experiments revealed that CD86 was the dominant CD28 ligand for generating the T FH cells that support GC development.
Graded Control of the microRNA-17-92 Cluster by CD28. The miR-17-92 cluster has recently been shown to promote T FH generation (17, 18) and is induced in mouse T cells stimulated with anti-CD3 and anti-CD28 (26). We found that naïve T cells stimulated with anti-CD3 and anti-CD28 up-regulated higher levels of miR-17, an indicator miR for expression of this cluster, than those stimulated with anti-CD3 alone and that lack of CD28 stimulation could not be substituted by provision of IL-2 (Fig. 5A) . To assess the impact of CD28 engagement using natural ligands rather than Abs, we activated naïve T cells in the presence of purified splenic B cells from CD80CD86
, or CD80CD86 −/− mice, which express graded levels of CD80 and CD86 (Fig. S6B ). This revealed a clear dose-dependent effect of CD80 and CD86 on miR-17 expression (Fig. 5B) . Additional experiments revealed that deficiency or blockade of CTLA-4 led to increased T-cell miR-17 expression (Fig. S9) . These data suggest that by altering expression levels of costimulatory ligands, CTLA-4 has the capacity to influence key controllers of the T FH differentiation program.
Discussion
Multiple studies demonstrate the association between the CTLA-4/CD28 axis and autoimmunity (27) (28) (29) . More recently, a link between T FH differentiation and autoimmunity has emerged (30, T FH cells provide a key link between T-cell activation and the ability to generate high-affinity class-switched Abs via GCs. The association between T FH and autoimmunity has sparked an increasing interest in understanding how T FH generation and function is regulated. It has been reported that a population of Qa1-restricted CD8 T cells expressing CXCR5 can regulate T FH numbers in a manner dependent on perforin expression (38) . More recently, a subset of regulatory T cells termed T FR (T-follicular regulatory) has been identified that enter the GC and have the capacity to limit T FH and GC B-cell numbers (39) (40) (41) . Thus, the magnitude of T FH and GC responses is likely controlled by specialized Treg.
A major portion of CTLA-4 function can be attributed to its role in Treg (9, 42) and CTLA-4 expression, along with IL-2 repression, is the minimal requirement to confer Treg-like suppressive activity (43) . One mechanism of action of CTLA-4 is the down-regulation of costimulatory ligands on APCs (7-10), which can occur via a process of transendocytosis (11) . This results in decreased availability of ligands for CD28-mediated costimulation of T cells. Accordingly, Treg-expressed CTLA-4 can directly control CD28 signaling in Tconv by restricting CD28 ligand availability. Intriguingly, Tconv can also use CTLA-4 to mediate transendocytosis (11), and we (44) and others (45) have shown that Tconv-expressed CTLA-4 can elicit regulation in a cell-extrinsic manner. This suggests a common mechanism of action for CTLA-4 regardless of the cell type on which it is expressed. Thus, CTLA-4, on both Treg and Tconv, can down-regulate costimulatory ligands and thereby decrease T-cell CD28 stimulation. Although one major impact of CTLA-4 function is clearly to prevent self-reactive T-cell activation, additional functions may include its impact on T-cell differentiation and B-cell responses as indicated here.
The mechanism used by T FR to regulate the GC response is not yet clear. Notably, T FR s express CTLA-4 at high levels (39), suggesting they are well placed to use the CTLA-4 pathway to elicit suppression. Indeed, T FR s were clearly detectable in GC induced by anti-CTLA-4 Ab treatment (Fig. S10) , consistent with the idea that despite their correct positioning T FR s are unable to regulate GCs in the absence of CTLA-4. Furthermore, in one study, T FR s were reported to express low levels of CD25 (39) , suggesting a decreased capacity to use IL-2 sequestration (46) as a suppressive mechanism. Indeed, consuming local IL-2 may be of limited value in regulating the T FH responses, as IL-2 itself inhibits T FH differentiation (47) (48) (49) (50) .
It has been shown that T FR s limit the outgrowth of nonantigen-specific B cells in the GC (39) , thereby regulating GC size. Indeed, the deletion of B cells that are unable to elicit T-cell help is a key selection step within the GC that permits affinity maturation of the humoral response. The importance of such deletion is exemplified by the lymphoproliferative disease that affects mice in which Fas-mediated apoptosis is blocked in GC B cells (51) . The simplest explanation for the capacity of T FR to control GC size is that they limit T FH number and thereby restrict the ability of T cells to rescue GC B cells from death. Because T FH homeostasis is tightly linked to the availability of costimulatory ligands on B cells (52, 53) , it is easy to envisage how T FR could use the CTLA-4 pathway to control T FH by downregulating costimulatory ligand expression on B cells.
T FH s are endowed with the capacity to solicit CD86 expression on B cells via production of IL-21 (54) or IL-4 (55). Thus, highaffinity B cells that competitively capture antigen from follicular dendritic cells, and productively engage with T FH s in the light zone of GCs, may be rewarded with cytokines that up-regulate their CD86 expression. This allows them to offer CD28 engagement to the T cells providing help, likely augmenting IL-21 production and beginning a feedback loop that will ensure entry of the clone into the long-lived plasma cell or memory B-cell pool.
That a complete block in CD28 signaling abrogates the GC response has been known for some time. We previously reported (6) that this reflected a requirement for CD28 to up-regulate CXCR5 on T cells, the chemokine receptor that allows them to respond to CXCL13 expressed in the B-cell follicle. Accordingly, in mice where CD28 signaling was blocked by transgenic expression of CTLA-4-Ig, T cells failed to up-regulate CXCR5; however, CXCR5 up-regulation, follicular migration, and GC formation could be restored if CD80/86 blockade was bypassed by injection of agonistic anti-CD28 (6). Thus, CD28 plays a critical role in resetting the T-cell chemokine receptor balance that permits T-cell localization to the B-cell follicles. Here we move beyond the simple presence or absence of costimulation and instead explore how the strength of CD28 signaling alters T-cell fate. We demonstrate that sensing of costimulatory ligands in vivo is analog and not digital-that is, it is not all or nothing but reflects the overall level of CD28 engagement. Commitment to a T FH phenotype appears to require a higher level of CD28 engagement than commitment to proliferation or CD62L down-regulation. This . ***P < 0.001, **P < 0.01, *P < 0.05; NS, not significant. isolated at day 3, and miR-17 mRNA levels were assessed. Graph shows collated data from three independent experiments. Statistical analysis was performed by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
may reflect the fact that such commitment also licenses the B-cell response and therefore serves as an additional checkpoint in the adaptive immune response. Indeed, our data suggest that the level of CD28 signaling directly couples the magnitude of the T-helper response to the magnitude of the B-cell response. In addition to CD28-mediated induction of CXCR5, ICOSderived signals are required to enhance T-cell motility to facilitate entry to the B-cell follicle (56) . Accordingly, the failure of ICOS-deficient T cells to enter B-cell follicles cannot be overcome by transgenic expression of CXCR5 (56) . The division of labor between CD28 and ICOS in control of T-cell help for B cells has been a topic of intense debate. We and others previously suggested a hierarchy of costimulatory interactions in which CD28 operates upstream of ICOS (57, 58) . This is consistent with CD28 being expressed on naïve T cells while ICOS is induced following T-cell activation (59) . Indeed, it was noted that restricting ICOS function to downstream of CD28 was key to maintaining two-signal control of T-cell responses (60) . We now extend this concept and suggest that CD28 and ICOS function are inherently coupled. Our data demonstrate that the strength of CD28 signaling in vivo translates directly into the level of ICOS surface expression induced on the T cell. This provides an elegant mechanism linking CD28 engagement to the ICOS-dependent activation of PI3K known to be critical for the generation of T FH s (61, 62) . Thus, neither CD28 nor ICOS alone is sufficient to induce the T FH program, consistent with microarray data obtained following independent engagement of these receptors (63) . Rather, our data suggest that CD28 and ICOS function together to confer the T FH phenotype. The long-range linkage disequilibrium reported at the CD28 and ICOS loci (64) may lock together variants that function coordinately to couple T-and B-cell function.
Although the CD28-dependent up-regulation of ICOS is likely to be a key step in driving T FH generation, it is not the sole mediator of the response. Accordingly, CD28 −/− mice overexpressing ICOS as a consequence of roquin mutation do not form spontaneous GCs (although GCs can be induced by immunization) (60) . Thus, overstimulation of CD28, as a consequence of CTLA-4 deficiency or blockade ( Figs. 1 and 2) , induces a distinct phenotype from overexpression of ICOS. Other mechanisms by which CD28 may promote T FH generation include regulation of the microRNA cluster 17-92, as shown here. Recent data revealed that expression of the miR-17-92 cluster is critical for the differentiation and function of T FH (17, 18) . Indeed, overexpression of miR-17-92 promotes T FH generation (17) , and transgenic expression of miR-17-92 in T cells can drive spontaneous T FH differentiation and GC formation, similar to our findings with CTLA-4 deficiency and blockade (18) . The functionally relevant targets of the miR-17-92 cluster are still unclear, but the mechanism of action is likely to include direct and indirect repression of genes that antagonize T FH differentiation. Control of genes that regulate the PI3K pathway (e.g., the PI3K antagonist PTEN and the AKT phosphatase PHLPP2) may be particularly important (17, 18) , consistent with the well-recognized role of PI3K in the GC response (61, 62) .
The relative contribution of CD86 and CD80 to T-cell-dependent Ab responses is still unclear. The dominant role for CD86 identified here is consistent with the demonstration that CD86 −/− mice show a more profound defect in GC formation than CD80 −/− mice (65) . Given the sequential interaction of T cells with dendritic cells (DCs) and B cells during humoral responses, this could reflect distinct cell type-specific or kinetic expression patterns between ligands. Of note, studies have documented the importance of either CD86 (52) or CD80 (53) on B cells for T FH generation and GC responses. It is possible that the nature and context of the antigenic challenge dictate the relative requirement for CD80 versus CD86, consistent with the capacity of strong adjuvants to restore the GC response in CD86 −/− mice (65) . Collectively our data demonstrate that fine-tuning the degree of CD28 engagement-for example, by CTLA-4-dependent downregulation of costimulatory ligands on DCs or GC B cells-results in tailored modulation of the T FH response. Thus, T-cell-dependent humoral immunity is tightly controlled by the CTLA-4 pathway.
Materials and Methods
Mice. BALB/c and DO11.10 mice were from The Jackson Laboratory and CD28 RT-PCR. Cells were purified by sorting (MoFlo, Dako Cytomation), and RNA was isolated using RNAzol B (Biogenesis), reverse transcribed and interrogated for IL-21 (TaqMan, Applied Biosystems) using the Stratagene MX3000P real-time PCR detection system. Gene expression was normalized to β-actin levels.
Immunohistochemistry and Confocal Microscopy. Acetone-fixed frozen 5-μm spleen sections were stained with sheep anti-IgD (Abcam) and rat anti-CD4 (BD Biosciences) or biotinylated peanut agglutinin (PNA; Vector Labs). Second step reagents were HRP-conjugated donkey anti-sheep IgG (Binding Site), biotinylated rabbit anti-rat Igs, followed by Streptavidin-ABComplexalkaline phosphate (Vector Labs). Staining was visualized using FastBlue and DAB (3,3′-diaminobenzidine; Sigma-Aldrich). We incubated 5-μm cryostat sections from rag2 −/− stomach with serum samples from CTLA-4-deficient, wild-type, or Ab-treated mice, as indicated. Bound Ab was detected with anti-mouse IgG-555, and sections were counterstained with DAPI. Images were captured by confocal microscopy (Zeiss LSM 510 Meta). , or anti-CTLA-4 Ab-treated mice. Total RNA was extracted using a mirVana miRNA Isolation Kit (Ambion, Life Technologies) and converted to cDNA with a TaqMan MicroRNA Reverse Transcription Kit. The miRNA expression levels of mouse miR-17 were established by real-time PCR using Taqman primers (Taqman, Life Technologies) and a 7500 Fast RT-PCR system (Applied Biosystems, Life Technologies). Expression was normalized against RNA from freshly isolated CD4+CD25-T cells and the sno202 housekeeping gene, with the ΔΔ cyclic threshold method used to calculate relative fold change.
In
Statistics. Statistical analysis was performed using Graphpad Prism version 5, and P values were calculated by two-tailed, unpaired t test for the means
